The market for therapeutics for basal cell and squamous cell carcinoma in North America was valued at USD 578.2 million in 2020; it is anticipated to increase to USD 2,353.4 million in 2028 at a CAGR of 16.1% from USD 825.6 million in 2021.

The market for therapeutics for basal cell and squamous cell carcinoma in North America was valued at USD 578.2 million in 2020; it is anticipated to increase to USD 2,353.4 million in 2028 at a CAGR of 16.1% from USD 825.6 million in 2021.